Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 24Sarcoma 10Breast 7Gastrointestinal 5Lymphoid 3Head & Neck 2Thoracic 1Gynecologic 1CNS 1

Conditions

Pleural Effusion, Malignant 1Neoplasm Metastasis 1Lung Neoplasms 1

Interventions

Carboplatin 1167Cisplatin 889Pemetrexed 845pembrolizumab 622Paclitaxel 608Docetaxel 539Gemcitabine 428Radiotherapy 390Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 296durvalumab 264Drug Therapy 260osimertinib 236atezolizumab 224Radiosurgery 194Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 131Ipilimumab 129130-nm albumin-bound paclitaxel 124Cetuximab 113Blood Specimen Collection 106anlotinib 105tislelizumab 103Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
talimogene laherparepvec × Thoracic × Clear all
NCT03597009 2021-04-20

A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Terminated
1 enrolled 12 charts
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡